(redirected from Belviq)


(lor-ca-ser-in) ,


(trade name)


Therapeutic: weight control agents
Pharmacologic: serotonin 2c receptor agonists
Pregnancy Category: X


In conjunction with a reduced-calorie diet and increased physical activity for chronic weight management in patients with a body mass index (BMI) of ≥30 kg/m2 or 27 kg/m2 with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia).


Acts as a serotonin 2C receptor agonist; increases satiety by activating 5–HT2C receptors located on anorexigenic neurons in the hypothalmus.

Therapeutic effects

Decreased appetite with subsequent weight loss and health benefits.


Absorption: Well absorbed following oral administration.
Distribution: Enters cerebrospinal fluid and central nervous system.
Metabolism and Excretion: Extensively metabolized by the liver; metabolites are mostly excreted in urine (92.3%), minimal amounts in feces (2.2%).
Half-life: 11 hr.

Time/action profile (weight loss)

POwithin 1 mo6–9 mounknown


Contraindicated in: Obstetric: Pregnancy (weight loss may result in fetal harm); Lactation: Breast feeding is not recommended; Pediatric: Not recommended for children <18 yr;Severe renal impairment/end stage renal disease.
Use Cautiously in: History of priapism or risk of priapism (including sickle-cell anemia, multiple myeloma, leukemia or penile deformity);History of congestive heart failure, bradycardia or heart block greater than first degree;History of suicidal thoughts/behavior;History of type 2 diabetes (weight loss may ↑ risk of hypoglycemia);Concurrent use of drugs metabolized by the CYP2D6 enzyme system;Moderate renal impairment;Severe hepatic impairment; Geriatric: Use should be based on age-related renal impairment.
Exercise Extreme Caution in: Concurrent use of serotoninergic or antidopaminergic agents.

Adverse Reactions/Side Effects

Central nervous system

  • neuroleptic malignant syndrome (life-threatening)
  • serotonin syndrome (life-threatening)
  • cognitive impairment
  • depression
  • dizziness
  • fatigue
  • psychiatric disorders
  • suicidality


  • valvulopathy (life-threatening)
  • bradycardia
  • hypertension
  • peripheral edema


  • constipation
  • dry mouth
  • nausea


  • priapism


  • hypoglycemia
  • ↑ prolactin


  • ↓ RBC count


Drug-Drug interaction

Concurrent use with serotonergic or antidopaminergic medications, including antipsychotics may ↑ risk of serotonin syndrome or neuroleptic malignant syndrome; use extreme caution.Concurrent use with serotonergic/dopaminergic agents that are potent 5–HT2B agonists may ↑ risk of cardiac valvulopathy.May ↑ blood levels and effects of other drugs metabolized by the CYP 2D6 system, including dextromethorphan ; locaserin is an inhibitor of the CYP 2D6 system.


Oral (Adults) 10 mg twice daily; discontinue if 5% weight loss has not been observed at 12 wk.


Tablets: 10 mg

Nursing implications

Nursing assessment

  • Monitor patients for weight loss and adjust concurrent medications (antihypertensives, antidiabetics, lipid-lowering agents) as needed.
  • Assess for serotonin syndrome (mental changes [agitation, hallucinations, coma], autonomic instability [tachycardia, labile BP, hyperthermia], neuromuscular aberrations [hyper-reflexia, incoordination], and/or GI symptoms [nausea, vomiting, diarrhea]), especially in patients taking other serotonergic drugs (SSRIs, SNRIs, triptans).
  • Monitor for signs and symptoms of neuroleptic malignant syndrome (hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, mental status changes) during therapy.
  • Assess for signs and symptoms of valvular heart disease (dyspnea, dependent edema, CHF, new cardiac murmur) during therapy. If these develop, consider discontinuing lorcaserin.
  • Monitor closely for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression. Discontinue lorcaserin if these occur.
  • Monitor for symptoms related to hyperprolactinemia (menstrual abnormalities, galactorrhea, gynecomastia).
  • Lab Test Considerations: Monitor CBC periodically during therapy. May cause leukopenia, lymphopenia, neutropenia, anemia, and ↓ WBC, hemoglobin, and hematocrit.
    • May cause ↑ prolactin levels.
    • Monitor blood sugar closely in patients with diabetes.

Potential Nursing Diagnoses

Disturbed body image (Indications)
Imbalanced nutrition: more than body requirements (Indications)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Oral: May be administered with or without food.

Patient/Family Teaching

  • Instruct patient to take lorcaserin as directed and not to increase dose.
  • May impair cognitive function. Caution patient to avoid driving or other activities that require alertness until response to medication is known.
  • Advise patient and family to notify health care professional if thoughts about suicide or dying, attempts to commit suicide; new or worse depression; new or worse anxiety; feeling very agitated or restless; panic attacks; trouble sleeping; new or worse irritability; acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking; other unusual changes in behavior or mood or if symptoms of serotonin syndrome, neuroleptic malignant syndrome, or valvular heart disease occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications, especially St. John's Wort.
  • Advise patients with diabetes to monitor blood sugar closely during therapy.
  • Inform male patient that priapism may occur. If an erection lasts longer than 4 hrs, whether painful or not, immediately discontinue lorcaserin and seek emergency attention.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

  • Decrease in weight and BMI. If 5% of baseline body weight is not lost by Week 12, discontinue lorcaserin, as it is unlikely patient will achieve and sustain clinically meaningful weight loss with continued treatment.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
This included [yen]11,859 million from Lenvima, [yen]10,227 million from anticancer agent Halaven, [yen]4,541 million from Fycompa, and [yen]989 million from antiobesity agent BELVIQ.
* Lorcaserin (Belviq), a selective serotonin 2C receptor agonist.
M2 EQUITYBITES-February 26, 2019-Eisai Inc submits sNDA with US FDA to update the labeling of anti-obesity agent BELVIQ (lorcaserin HCl)
Global Banking News-February 26, 2019-Eisai Inc submits sNDA with US FDA to update the labeling of anti-obesity agent BELVIQ (lorcaserin HCl)
M2 PHARMA-February 26, 2019-Eisai Inc submits sNDA with US FDA to update the labeling of anti-obesity agent BELVIQ (lorcaserin HCl)
has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in Brazil to Eurofarma Laboratorios S.A.
It's been available in the US (where it's called Belviq) since 2012, but is currently unlicensed in Europe.
Bellamine suggested competition from big pharma could be a hurdle for manufacturers, pointing to the recent FDA approval of four pharmaceutical drugs for managing obesity, including lorcaserin (Belviq).
(8,9) Phentermine/ topiramate extended-release (ER) (Qsymia) and lorcaserin (Belviq) were approved in 2012, (10,11) and naltrexone sustained release (SR)/bupropion SR (Contrave) and liraglutide 3 mg (Saxenda) were approved in 2014 (12,13) (table (9,14-39)).
FDA approves Belviq to treat some overweight or obese adults.
(8,9) Phentermine/topiramate extended-release (ER) (Qsymia) and lorcaserin (Belviq) were approved in 2012, (10,11) and naltrexone sustained release (SR)/bupropion SR (Contrave) and liraglutide 3 mg (Saxenda) were approved in 2014 (12,13) (TABLE (9,14-39)).